NCT01066442View on ClinicalTrials.gov

Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

273

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Parkinson's Disease

Interventions

DRUG

BF2.649 (Pitolisant)

1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D

Trial Locations (1)

35039

Klinik für Neurologie Universitätsklinikum, Marburg

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bioprojet

OTHER